Neuropsychiatrische Störungen bei der Parkinson-Erkrankung

Zusammenfassung

In dieser Übersicht wird der aktuelle Stand zu den häufigsten neuropsychiatrischen Störungen beim idiopathischen Parkinson-Syndroms (IPS) erörtert. Depression, Halluzinationen und Demenz betreffen im Langzeitverlauf die Mehrheit der Parkinson-Patienten. Diese prägen im Verlauf die Lebensqualität in größerem Ausmaß als die die Parkinson-Krankheit kennzeichnenden motorischen Kardinalsymptome Akinese, Tremor und Rigor. Impulskontrollstörungen, zu einem großen Teil iatrogen, sind erst in den vergangenen Jahren vermehrt in die Aufmerksamkeit gerückt.

Summary

Neuropsychiatric disorders have a great impact on the management of Parkinson’s disease (PD). Depression, dementia and hallucinations affect virtually all PD patients during the course of their disease and their influence on quality of life is greater than the cardinal signs akinesia, tremor and rigidity which characterize PD. Impulse control disorders, to a large extent iatrogenic complication, have drawn increased attention in recent years and will also be discussed.

Schlüsselwörter

Idiopathisches Parkinson-Syndrom - Depression - Demenz - Impulskontrollstörung - Halluzi-nation - Dopaminergika

Keywords

Parkinson’s disease - depression - dementia - hallucinations - impulse control disorders - dopaminergics

• Literatur

• 1 Aarsland D. et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60 (03) 387-92.
• 2 Aarsland D. et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75 (12) 1062-9.
• 3 Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18 (10) 937-41.
• 4 Antonini A. et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 2009; 8 (10) 929-37.
• 5 Barone P. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9 (06) 573-80.
• 6 Barone P. et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease : a national multicenter parallel-group randomized study. J Neurol 2006; 253 (05) 601-7.
• 7 Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol 2002; 25 (02) 107-10.
• 8 Bilal L, Tsai C, Gasper JJ, Ndlela JC. Parkinsonism with intramuscular ziprasidone. Am J Psychiatry 2005; 162 (12) 2392-3.
• 9 Boecker H. et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007; 64 (07) 984-8.
• 10 Burn D. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21 (11) 1899-907.
• 11 Dautzenberg PL. et al. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson’s disease. Int J Geriatr Psychiatry 2003; 18 (06) 555-6.
• 12 de Lau LM. et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005; 62 (08) 1265-9.
• 13 Demet EM. et al. Sleep deprivation therapy in depressive illness and Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23 (05) 753-84.
• 14 Devos D. et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23 (06) 850-7.
• 15 Diederich NJ. et al. Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 5 (06) 331-42.
• 16 Dubois B. et al. Donepezil in Parkinson’s disease dementia: A randomized, double-blind efficacy and safety study. Mov Disord 2012; 27 (10) 1230-8.
• 17 Emre M. et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351 (24) 2509-18.
• 18 Emre M. et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8: 613-8.
• 19 Epstein CM. et al. An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson’s disease. Clin Neurophysiol 2007; 118 (10) 2189-94.
• 20 Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson’s disease. Mov Disord 2009; 24 (11) 1561-70.
• 21 Faber R, Trimble M. Electroconvulsive therapy in Parkinson´s disease and other movement disorders. Mov Disord 1991; 6: 293-303.
• 22 Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson’s disease. Neurology 1998; 50 (05) 1456-8.
• 23 Giladi N. et al. Rivastigmine for dementia in patients with Parkinson’s disease. Acta Neurol Scand 2003; 108 (05) 368-73.
• 24 Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55 (06) 789-94.
• 25 Grace J. et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13 (02) 199-205.
• 26 Group TFCPS. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 1999; 353 9169 2041-2.
• 27 Haupt M. et al. [Improvement of agitation and anxiety in dementia patients after psychoeducative training of their caregivers]. Fortschr Neurol Psychiatr 2000; 68 (05) 216-23.
• 28 Hely MA. et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23 (06) 837-44.
• 29 Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998; 43 (01) 69-72.
• 30 Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996; 61 (03) 324-5.
• 31 Kaufer DI. A case study in the treatment of dementia with Lewy bodies. Acta Psychiatr Scand 2004; 110 (01) 73-5.
• 32 Kulisevsky J. et al. Acute effects of immediate and controlled-release levodopa on mood in Parkinson’s disease: A double-blind study. Mov Disord 2007; 22 (01) 62-7.
• 33 Kumar A. et al. Clozapine for the treatment of neurogenic bladder. Neurourol Urodyn 2007; 26 (04) 537-9.
• 34 Kurlan R, Cummings J, Raman R, Thal L. Quetia-pine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68 (17) 1356-63.
• 35 Lemke MR. Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56 (08) 354-7.
• 36 Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 2009; 24 (08) 1217-21.
• 37 Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev. 2004 (2): CD003945.
• 38 Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev. 2006 (1): CD004747.
• 39 Manfredi PL. et al. Opioid treatment for agitation in patients with advanced dementia. Int J Geriatr Psychiatry 2003; 18 (08) 700-5.
• 40 Marsh L. et al. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21 (02) 148-58.
• 41 McGaffigan S, Bliwise DL. The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs Aging 1997; 10 (01) 10-7.
• 42 McKeith I. et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356 9247 2031-6.
• 43 McKeith IG. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (12) 1863-72.
• 44 Meehan KM. et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26 (04) 494-504.
• 45 Menza M. et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72 (10) 886-92.
• 46 Morgante L. et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27 (04) 153-6.
• 47 Moum SJ. et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012; 7 (01) e29768.
• 48 Oertel W. et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson’s disease dementia : a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 2008; 31 (01) 79-94.
• 49 Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?. Neurology 2009; 72 (10) 868-9.
• 50 Olin JT. et al. A pilot randomized trial of carbamaze-pine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9 (04) 400-5.
• 51 Ondo WG. et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17 (05) 1031-5.
• 52 Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005; 20 (08) 958-63.
• 53 Parkinson-Study-Group.. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340 (10) 757-63.
• 54 Paus S. et al. Bright light therapy in Parkinson’s disease: A pilot study. Mov Disord 2007; 22 (10) 1495-8.
• 55 Pintor L. et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012; 35 (02) 61-6.
• 56 Rabey JM. et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22 (03) 313-8.
• 57 Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67 (01) 58-63.
• 58 Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16 (06) 1171-4.
• 59 Reijnders JS. et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008; 23 (02) 183-9.
• 60 Richard IH. et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78 (16) 1229-36.
• 61 Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother 2001; 35 (02) 202-5.
• 62 Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10 (03) 229-38.
• 63 Tariot PN. et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155 (01) 54-61.
• 64 Thobois S. et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain 2010; 133 Pt 4 1111-27.
• 65 Thomas A. et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68 (03) 400-4.
• 66 Thorgrimsen L, Spector A, Wiles A, Orrell M. Aroma therapy for dementia. Cochrane Database Syst Rev. 2003 (3): CD003150.
• 67 van Eimeren T. et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010; 75 (19) 1711-6.
• 68 Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol 2011; 24 (04) 324-30.
• 69 Voon V. et al. Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol 2011; 69 (06) 986-96.
• 70 Weintraub D. et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67 (05) 589-95.
• 71 Weintraub D. et al. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol 2003; 16 (03) 178-83.
• 72 Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003 (3): CD003672.
• 73 Zarate CA. et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56 (01) 54-60.
• 74 Schneider C, Storch A. Skalen und Scores zur Erfassung nichtmotorischer Symptome beim Morbus Parkinson. Nervenheilkunde 2012; 31: 879-883.